Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 4Terminated 2Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Neoplasms 9Carcinoma, Hepatocellular 5Squamous Cell Carcinoma of Head and Neck 4Melanoma 3Colorectal Neoplasms 3Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Head and Neck Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Sarcopenia 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Myositis 1Metastatic Colorectal Adenocarcinoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Liver Neoplasms 1Hyperthermia 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Heart Diseases 1Glioma 1Eye Diseases 1Esophageal Squamous Cell Carcinoma 1

Interventions

Carboplatin 41Paclitaxel 40pembrolizumab 38Cyclophosphamide 23Gemcitabine 22130-nm albumin-bound paclitaxel 21Doxorubicin 18Cisplatin 18Albumin-Bound Paclitaxel 18atezolizumab 16Taxes 15Capecitabine 13veliparib 10Nivolumab 9Docetaxel 9Bevacizumab 9olaparib 8liposomal doxorubicin 7Everolimus 7spartalizumab 6durvalumab 6Epirubicin 6trametinib 5pegfilgrastim 5eribulin 5Irinotecan 5Filgrastim 5iniparib 4binimetinib 4apatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Triple Negative Breast Neoplasms × Immune Checkpoint Inhibitors × Clear all
NCT03504488 2025-01-15

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

BioAtla, Inc.

Phase 1/2 Completed
132 enrolled
BreastDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Melanoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡